BioSpace News Archive

Rezolute, Inc. for serious metabolic and rare diseases, today announced that Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute, will participate in a fireside chat during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1:00 p.m. ET in New York City.

Olink Holding AB reported the publication of a landmark study using the Olink Explore platform to identify proteins in the blood that may provide a 7-year warning for various cancers.

Bionano Genomics, Inc. announced the Company’s robust participation at two upcoming cytogenetics conferences.

Werewolf Therapeutics, Inc. today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside at 1:00 PM ET on June 6 at the Jefferies Global Healthcare Conference, taking place June 4-6, 2024, in New York City, New York.

Tonix Pharmaceuticals Holding Corp. today announced two poster presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held May 28-31, 2024 in Miami Beach, Fla. Copies of the presentations are available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.

Aktis Oncology today announced the promotion of Tyler Benedum, Ph.D., to Chief Technical Officer, effective immediately.

Lineage Cell Therapeutics, Inc. today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention, on Tuesday June 4th, 2024, at 2:30pm in Theater 3.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the introduction of its Modular and Fast Track viral vector technology (tech) transfer frameworks.

Sinopia Biosciences, Inc. announced today that it has been awarded a Small Business Innovation Research (SBIR) grant from the National Institute of General Medical Sciences (NIGMS) to advance its computational drug discovery LEarn And DiScover (LEADS™) platform and explore applications in oncology and immunology.

ChromaTan, a bioprocessing and biotools advanced biomanufacturing technology platform development company, is excited to announce the award of NIH IIB grant of $2M from the National Institute of General Medical Sciences, for the development and integration of ChromaTan’s novel BioRMB™ single-use, column-free, steady-state continuous counter-current elution technology for manufacturing AAVs.